Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for severe chronic hand eczema after inadequate response or intolerance to alitretinoin
NL-OMON48247Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic hand dermatitis (CHE) and hand dermatitis comparing Dupilumab with Placebo (2 arms). Primary endpoints: HECSI-75 response, Patch test positivity change and 1 more. Started Aug 2020; status: active, not recruiting.
02
Drugs
03
Conditions
chronic hand dermatitis (CHE)hand dermatitis
Beyond the preview
Go deeper on NL-OMON48247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48247.